Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ÀüÀ̼º ¼ö¸·¾ÏÁ¾Áõ Breast Cancer with Leptomeningeal Metastasis

´ëÇÑ¿Ü°úÇÐȸÁö 2004³â 66±Ç 3È£ p.239 ~ 242
ÀÌÈ£±Õ, ÇÏÀÏÁÖ, ±èÁ¤Ã¶, ÃÖ¼öÁø³ª, À±Á¤ÇÑ, Á¦°¥¿µÁ¾,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÈ£±Õ ( Lee Ho-Kyun ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

ÇÏÀÏÁÖ ( Ha Il-Joo ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±èÁ¤Ã¶ ( Kim Jung-Chul ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÃÖ¼öÁø³ª ( Choi Soo-Jin-Na ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
À±Á¤ÇÑ ( Yoon Jung-Han ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Á¦°¥¿µÁ¾ ( Jaegal Young-Jong ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Leptomeningeal metastsis (LM) is a disease where the tumor cells involves the leptomeninges. Breast cancer, of all solid tumors, is the primary tumor most frequently associated with leptomeningeal metastasis. Leptomeningeal metastasis originating from breast cancer is usually detected at an advanced stage, so its evaluation and aggressive treatment are difficult. Leptomeningeal metastasis, from solid tumors, has been reported to inexorably lead to death within 4 to 6 weeks if left untreated. ntrathecal or Intraventricular chemotherapy and radiotherarpy are the mainstays of treatment. Even though controversial, systemic chemotherapy, with regional radiotherapy, can also improve the neurological outcome and survival, without neurotoxicity. Here, two patients with leptomeningeal metastasis, originating from breast cancer, their clinical course and treatment modalities are reported.

Å°¿öµå

À¯¹æ¾Ï;¼ö¸·¾ÏÁ¾Áõ;Breast cancer;Leptomeningeal metastasis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS